{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:02:30Z","timestamp":1788321750762,"version":"build-2803163510"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T00:00:00Z","timestamp":1539216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Lundbeck Pharmaceuticals Ltd."},{"DOI":"10.13039\/100009655","name":"Sunovion Pharmaceuticals Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"crossref"}]},{"name":"UCB Pharma and LivaNova PLC"},{"name":"BIAL \u2013 Portela & Ca, S.A"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.eplepsyres.2018.08.011","type":"journal-article","created":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T15:45:48Z","timestamp":1535557548000},"page":"80-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures"],"prefix":"10.1016","volume":"147","author":[{"given":"Bassel","family":"Abou-Khalil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7370-3004","authenticated-orcid":false,"given":"Aashit","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Ryvlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi M.","family":"Specchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Gama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Grinnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JungAh","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2018.08.011_bib0005","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1212\/CON.0000000000000289","article-title":"Antiepileptic drugs","volume":"22","author":"Abou-Khalil","year":"2016","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1016\/j.eplepsyres.2018.08.011_bib0010","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/j.1499-1654.2000.001597.x","article-title":"Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy","volume":"41","author":"Barcs","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.08.011_bib0015","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.eplepsyres.2010.01.014","article-title":"Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy","volume":"89","author":"Ben-Menachem","year":"2010","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2018.08.011_bib0020","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1528-1157.1998.tb01356.x","article-title":"Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?","volume":"39","author":"Besag","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.08.011_bib0025","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.yebeh.2017.04.019","article-title":"Adjunctive eslicarbazepine acetate: a pooled analysis of three phase III trials","volume":"72","author":"Biton","year":"2017","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2018.08.011_bib0030","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1046\/j.1528-1157.2001.43600.x","article-title":"Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels: comparison with carbamazepine","volume":"42","author":"Bonifacio","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.08.011_bib0035","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1111\/epi.12250","article-title":"Cav 2.3 (R-type) calcium channels are critical for mediating anticonvulsive and neuroprotective properties of lamotrigine in vivo","volume":"54","author":"Dibue","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.08.011_bib0040","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1528-1167.2008.01946.x","article-title":"Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study","volume":"50","author":"Elger","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.08.011_bib0045","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1212\/01.CON.0000431380.21685.75","article-title":"Antiepileptic drug treatment: new drugs and new strategies","volume":"19","author":"French","year":"2013","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1016\/j.eplepsyres.2018.08.011_bib0050","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0006-8993(98)00180-2","article-title":"Lamotrigine may limit pathological excitation in the hippocampus by modulating a transient potassium outward current","volume":"791","author":"Grunze","year":"1998","journal-title":"Brain Res."},{"key":"10.1016\/j.eplepsyres.2018.08.011_bib0055","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/jamaneurol.2014.808","article-title":"Effectiveness of antiepileptic drug combination therapy for partial-onset seizures based on mechanisms of action","volume":"71","author":"Margolis","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.eplepsyres.2018.08.011_bib0060","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/11587550-000000000-00000","article-title":"A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs","volume":"24","author":"Sake","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.eplepsyres.2018.08.011_bib0065","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/epi.12894","article-title":"Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: results of a phase III, double-blind, randomized, placebo-controlled trial","volume":"56","author":"Sperling","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.08.011_bib0070","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/01.wnr.0000246323.66438.94","article-title":"Lamotrigine is an open-channel blocker of the nicotinic acetylcholine receptor","volume":"18","author":"Valles","year":"2007","journal-title":"Neuroreport"},{"key":"10.1016\/j.eplepsyres.2018.08.011_bib0075","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1124\/jpet.110.171108","article-title":"The anticonvulsive drug lamotrigine blocks neuronal \u03b14\u03b22 nicotinic acetylcholine receptors","volume":"335","author":"Zheng","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.eplepsyres.2018.08.011_bib0080","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1046\/j.1528-1157.2002.51401.x","article-title":"Neocortical potassium currents are enhanced by the antiepileptic drug lamotrigine","volume":"43","author":"Zona","year":"2002","journal-title":"Epilepsia"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121118302948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121118302948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:40:37Z","timestamp":1760276437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121118302948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":16,"alternative-id":["S0920121118302948"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2018.08.011","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2018.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}